Pharmacy review ROI: the business case for claims managers

Build the financial case for medication review as a core claims management investment

Published: 3 April 2026 | Updated: 3 April 2026

Understanding pharmacy review as an investment

Pharmacy review services cost money upfront. A specialist medication review typically costs between $500 and $1,500 depending on claim complexity. For claims managers managing tight budgets, this can feel like discretionary spending rather than essential investment. However, when you model the financial impact properly, pharmacy review becomes one of the highest-ROI interventions available to you in claims management.

The key is understanding that pharmacy review is not a cost; it is an investment with measurable financial returns. Like case management itself, rehabilitation, or vocational services, medication review generates savings that exceed its cost multiple times over. Your role is calculating that return accurately so you can make informed allocation decisions.

The cost side of the equation

First, clarify the actual cost of pharmacy review. Costs vary based on complexity:

These costs are typically one-time or episodic (quarterly or semi-annually for complex claims). Importantly, they are minor in comparison to total claim spend. A claim costing $100,000 over its lifetime investing 1% ($1,000) in pharmacy review is standard claims management practice.

The direct savings from pharmacy review

Pharmacy review generates savings through several direct mechanisms:

1. Medication cost reduction

This is the most straightforward saving. Pharmacy review identifies medications to deprescribe or replace with lower-cost alternatives. Average savings:

• Deprescribing medications: eliminates full cost of those medications
• Switching to generics: saves 50-80% compared to branded equivalents
• Simplifying regimens: reduces pharmacy dispensing and administration costs
• Average monthly medication cost reduction: $300-800 per claimant

For a claimant on an eight-medication regimen costing $1,500 monthly, reduction to four medications costing $600 monthly represents $900 monthly savings, or $10,800 annually.

2. Reduced medication-related complications

Inappropriate medications cause adverse events that drive additional medical costs. A single medication-related adverse event (fall fracture, GI bleed, hospitalisation) can cost $10,000-50,000 to manage. Preventing these events through appropriate medication management is high-value savings:

• Falls from sedating medications: prevent 1-2 falls per 100 claimants through deprescribing
• GI complications from NSAIDs: prevent hospitalisation through medication review
• Cognitive decline from multiple medications: improve engagement in rehabilitation
• Withdrawal complications: prevent emergency department visits through structured deprescribing

3. Improved rehabilitation engagement

Medication-induced sedation or cognitive impairment limits claimant participation in physiotherapy, work retraining, and rehabilitation services. Deprescribing sedating medications allows increased rehabilitation engagement. The outcome:

• Improved functional capacity from greater rehabilitation participation
• Faster progression toward return to work
• Reduced total rehabilitation costs through better efficiency

Modeling ROI: a practical example

Here is a realistic case demonstrating pharmacy review ROI:

Selecting claims for pharmacy review investment

Not every claim warrants pharmacy review investment, though many do. Use these criteria to prioritise claims with highest ROI potential:

Claims that should receive pharmacy review

• Polypharmacy claims: Any claimant on five or more regular medications
• High-cost pharmacy claims: Monthly medication costs exceeding $1,000
• Long-tail claims: Claims extending beyond 24 months post-injury without clear functional progress
• Rehabilitation plateau claims: Claimants not progressing in rehabilitation despite adequate time and treatment
• Sedation-limited claims: Sedating medications limiting return-to-work capacity
• Closure preparation claims: Severe claims approaching transition to ongoing management phase

Claims with lower ROI potential

• Simple acute claims with 1-2 injury-related medications
• Fully resolved claims with short expected duration remaining
• Claims where claimant is already making good functional progress
• Medication regimens already optimised by specialist medical team

Direct savings calculator

Use this framework to estimate pharmacy review ROI for a specific claim:

Secondary benefits beyond direct savings

While direct medication savings are substantial, pharmacy review delivers additional value that compounds ROI:

Claim closure acceleration

When medication barriers to closure are removed, claims close months earlier. Each month of acceleration saves money across all cost categories. Accelerating claim closure by three months on a claim averaging $50,000 total cost yields approximately $12,500 in overall cost reduction.

Return-to-work acceleration

Improved medication regimen allows faster return to work. Each month of work return achieved reduces claim costs and improves claimant outcomes. For a $100,000 claim, each month of work return acceleration may represent $2,000-5,000 in cost avoidance.

Reduced complication rates

Appropriate medication management reduces medication-related complications. Preventing a single fall fracture, hospitalisation, or withdrawal event saves $10,000-50,000 per incident. On a caseload of 100 claims reviewed, preventing 1-2 serious adverse events justifies the entire program investment.

Improved claimant satisfaction and engagement

Claimants feel better on appropriate medications. Improved engagement improves outcomes and reduces disputes. While harder to quantify, satisfaction improvements have real value in reducing claims management friction and improving cooperation on closure planning.

Risk mitigation

Appropriate medication management reduces liability risk. Medication-related adverse events can trigger complaints, litigation, or regulatory scrutiny. Professional medication review provides documentation that medication management decisions were made with specialist input, improving your defensive position.

Program-level ROI: portfolio approach

Rather than reviewing individual claims, consider pharmacy review as a portfolio program. Estimate ROI across your claims cohort:

• Portfolio size: 1,000 active claims
• Polypharmacy prevalence: 15% (150 claims with 5+ medications)
• High-cost pharmacy: 10% (100 claims with $800+ monthly medication cost)
• Target review population: 200 claims (combining groups with overlap)
• Cost per review: $900 average (mix of complexities)
• Total program investment: $180,000
• Average savings per reviewed claim: $8,000 (first year direct medication savings)
• Total first-year program savings: 200 x $8,000 = $1,600,000
• Program ROI: ($1,600,000 - $180,000) / $180,000 = 7.9x return

A portfolio approach to pharmacy review, targeting 15-20% of your claims for specialist review, delivers program-level ROI of 5-10x, positioning medication management as one of your highest-value case management investments.

Overcoming ROI objections

Objection: "Pharmacy reviews cost too much."

Response: Review cost is 0.5-1.5% of total claim spend for typical claims. The ROI typically returns the investment within 1-3 months, making it a high-efficiency use of claims resources.

Objection: "Medication reductions won't happen. Doctors won't deprescribe."

Response: Specialist pharmacy recommendations consistently result in medication changes. Deprescribing is increasingly standard medical practice. Structured recommendations with evidence improve uptake significantly.

Objection: "The savings are uncertain. It's better to invest in proven interventions like rehabilitation."

Response: Medication savings are measurable and documented through pharmacy records. Rehabilitation and medication optimisation are complementary, not competing. The data shows both are high-ROI investments that work best together.

Making the case to leadership

When building the business case for pharmacy review investment, focus on these elements:

• Direct, measurable savings (medication cost reduction)
• Secondary benefits (claim acceleration, complication prevention)
• Portfolio approach (program ROI, not individual claim ROI)
• Risk mitigation (regulatory compliance, adverse event prevention)
• Outcomes improvement (faster return to work, better claimant outcomes)
• Competitive advantage (differentiation in claims management approach)

The financial case is compelling: pharmacy review is among the highest-ROI claims management investments available. Your challenge as a claims manager is allocating resources to capture this value systematically.